X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1163) 1163
index medicus (1089) 1089
prasugrel hydrochloride (838) 838
ticlopidine - analogs & derivatives (754) 754
clopidogrel (639) 639
male (622) 622
platelet aggregation inhibitors - therapeutic use (564) 564
prasugrel (564) 564
female (544) 544
middle aged (475) 475
piperazines - therapeutic use (451) 451
thiophenes - therapeutic use (451) 451
ticlopidine - therapeutic use (432) 432
cardiac & cardiovascular systems (419) 419
aged (410) 410
percutaneous coronary intervention (388) 388
treatment outcome (378) 378
adenosine - analogs & derivatives (364) 364
acute coronary syndrome - drug therapy (346) 346
platelet aggregation inhibitors - adverse effects (338) 338
platelet aggregation inhibitors - administration & dosage (326) 326
acute coronary syndromes (322) 322
ticlopidine - administration & dosage (257) 257
ticagrelor (247) 247
piperazines - administration & dosage (244) 244
thiophenes - administration & dosage (244) 244
adenosine - therapeutic use (241) 241
piperazines - adverse effects (241) 241
purinergic p2y receptor antagonists - therapeutic use (241) 241
thiophenes - adverse effects (241) 241
ticlopidine - adverse effects (241) 241
aspirin (232) 232
abridged index medicus (222) 222
platelet aggregation - drug effects (205) 205
hemorrhage - chemically induced (200) 200
platelet aggregation inhibitors - pharmacology (198) 198
prasugrel hydrochloride - therapeutic use (197) 197
pharmacology & pharmacy (190) 190
piperazines - pharmacology (190) 190
thiophenes - pharmacology (186) 186
blood platelets - drug effects (184) 184
risk factors (184) 184
drug therapy, combination (177) 177
acute coronary syndrome (175) 175
time factors (164) 164
antiplatelet therapy (159) 159
cardiovascular (158) 158
hematology (157) 157
purinergic p2y receptor antagonists - administration & dosage (156) 156
coronary heart disease (154) 154
prasugrel hydrochloride - administration & dosage (153) 153
peripheral vascular disease (151) 151
aspirin - therapeutic use (150) 150
prospective studies (148) 148
adult (144) 144
acute coronary syndrome - therapy (141) 141
inhibition (141) 141
myocardial infarction - drug therapy (138) 138
purinergic p2y receptor antagonists - adverse effects (138) 138
myocardial-infarction (137) 137
intervention (135) 135
cardiac patients (131) 131
platelet function tests (128) 128
stents (128) 128
trial (127) 127
ticlopidine - pharmacology (122) 122
blood platelets (121) 121
platelet aggregation inhibitors - pharmacokinetics (120) 120
aggregation (119) 119
drug therapy (119) 119
prasugrel hydrochloride - adverse effects (119) 119
care and treatment (117) 117
platelet inhibition (117) 117
dose-response relationship, drug (114) 114
heart attacks (114) 114
artery-disease (110) 110
piperazines - pharmacokinetics (109) 109
thiophenes - pharmacokinetics (107) 107
thrombosis (105) 105
elevation myocardial-infarction (104) 104
platelet reactivity (103) 103
adenosine - administration & dosage (102) 102
adenosine - adverse effects (100) 100
medicine, general & internal (99) 99
animals (98) 98
purinergic p2 receptor antagonists (97) 97
purinergic p2y receptor antagonists - pharmacology (97) 97
randomized controlled trials as topic (97) 97
cardiology (92) 92
active metabolite (91) 91
aspirin - administration & dosage (89) 89
outcomes (88) 88
follow-up studies (87) 87
stent thrombosis (86) 86
blood platelets - metabolism (85) 85
double-blind (85) 85
double-blind method (85) 85
percutaneous coronary intervention - adverse effects (85) 85
analysis (84) 84
mortality (84) 84
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1189) 1189
German (25) 25
French (9) 9
Italian (8) 8
Turkish (7) 7
Russian (6) 6
Spanish (4) 4
Polish (3) 3
Chinese (1) 1
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
Japanese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Pharmaceutical Sciences, ISSN 0022-3549, 09/2019, Volume 108, Issue 9, pp. 2842 - 2857
Prasugrel hydrochloride is the active ingredient in Effient™, a thienopyridine platelet inhibitor. An extensive study of the degradation chemistry of prasugrel... 
prasugrel | effient | degradation products | impurities | forced degradation | degradation | stress testing | structure elucidation | stability
Journal Article
Journal of Liquid Chromatography & Related Technologies, ISSN 1082-6076, 01/2018, Volume 41, Issue 1, pp. 14 - 23
Journal Article
Circulation, ISSN 0009-7322, 11/2016, Volume 134, Issue 21, pp. 1603 - 1612
Journal Article
Journal Article
Journal Article
Asian Journal of Chemistry, ISSN 0970-7077, 2013, Volume 25, Issue 14, pp. 7783 - 7789
Prasugrel hydrochloride (1), an important platelet inhibitor is used for the reduction of thrombotic cardiovascular events. During laboratory optimization and... 
Prasugrel | Related substances | Impurity profile | CHEMISTRY, MULTIDISCIPLINARY
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 06/2017, Volume 117, Issue 8, pp. 1582 - 1587
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2016, Volume 374, Issue 7, pp. 625 - 635
Journal Article
Clinical Research in Cardiology, ISSN 1861-0684, 4/2016, Volume 105, Issue 4, pp. 349 - 355
Morphine decreases the concentrations and effects of clopidogrel, which could lead to treatment failure in myocardial infarction.To clarify whether more potent... 
Prasugrel | Medicine & Public Health | Drug interactions | Morphine | Platelet function tests | Cardiology | Vasodilator-stimulated phosphoprotein | MORTALITY | PATHWAYS | CARDIAC & CARDIOVASCULAR SYSTEMS | PHOSPHORYLATION | REPERFUSION | ACUTE CORONARY SYNDROMES | CLOPIDOGREL | PLATELET INHIBITION | ACUTE MYOCARDIAL-INFARCTION | INTERVENTION | ACTIVE METABOLITE | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Male | Purinergic P2Y Receptor Antagonists - blood | Drug Monitoring - methods | Healthy Volunteers | Platelet Aggregation Inhibitors - blood | Young Adult | Purinergic P2Y Receptor Antagonists - adverse effects | Tandem Mass Spectrometry | Austria | Analgesics, Opioid - adverse effects | Drug Interactions | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Chromatography, Liquid | Adult | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Prasugrel Hydrochloride - administration & dosage | Prasugrel Hydrochloride - pharmacokinetics | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Risk Assessment | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Prasugrel Hydrochloride - adverse effects | Cross-Over Studies | Analgesics, Opioid - administration & dosage | Morphine - administration & dosage | Morphine - adverse effects | Prasugrel Hydrochloride - blood | Medical colleges | Metabolites | Vasodilators | Clinical trials | Liquid chromatography | Mass spectrometry | Index Medicus | Original Paper
Journal Article
CrystEngComm, ISSN 1466-8033, 10/2011, Volume 13, Issue 19, pp. 5737 - 5743
Ticlopidine hydrochloride (TICLID (R)) is a platelet antiaggregating agent whose use as a potent antithrombotic pharmaceutical ingredient is widespread, even... 
STROKE | RECEPTOR | PRASUGREL | CRYSTALLOGRAPHY | CHEMISTRY, MULTIDISCIPLINARY | Drugs | Solid state | Hydrochlorides | Crystallization | Crystals | Cations | Platelets | Symmetry
Journal Article
by Sibbing, Dirk and Aradi, Dániel and Aradi, Daniel and Jacobshagen, Claudius and Gross, Lisa and Trenk, Dietmar and Geisler, Tobias and Orban, Matthias and Orban, Martin and Hadamitzky, Martin and Merkely, Béla and Kiss, Róbert Gábor and Komócsi, András and Dézsi, Csaba A and Dézsi, Csaba András and Dézsi, András Döme and Holdt, Lesca and Felix, Stephan and Felix, Stephan B and Parma, Zofia and Parma, Radoslaw and Klopotowski, Mariusz and Schwinger, Robert and Schwinger, Robert H G and Rieber, Johannes and Huber, Kurt and Neumann, Franz-Josef and Koltowski, Lukasz and Mehilli, Julinda and Huczek, Zenon and Massberg, Steffen and Lesiak, Maciej and Komosa, Anna and Kowara, Michal and Rymuza, Bartosz and Malek, Lukasz and Veress, Gábor and Lux, Árpád and Papp, Judit and Kovács, Andrea and Amer, Sayour and Ruzsa, Zoltán and Róna, Szilárd and Ili, Renáta and Ungi, Imre and Nagy, Ferenc and Zweiker, Robert and Tóth-Gayor, Gábor and Haller, Paul and von Scheidt, Wolfgang and Blüthgen, Andreas and Leggewie, Stefan and Kreider-Stempfle, Hans Ulrich and Remp, Thomas and Kara, Kaffer and Mügge, Andreas and Wutzler, Alexander and Fichtlscherer, Stephan and Zeiher, Andreas M and Seeger, Florian and Hinterseer, Martin and König, Andreas and Lederle, Susanne and Czepluch, Frauke and Maier, Lars and Schillinger, Wolfgang and Sossalla, Samuel and Hummel, Astrid and Karakas, Mahir and Sydow, Karsten and Rudolph, Tanja and Halbach, Marcel and Gori, Tommaso and Münzel, Thomas and May, Andreas and Gerstenberg, Carsten-Manuel and Pilecky, David and Deichstetter, Markus and Kääb, Stefan and Löw, Anja and Sattler, Stefan and Deuschl, Sabine and Teupser, Daniel and Mudra, Harald and Räder, Thomas and Schütz, Torsten and Vahldiek, Felix and Divchev, Dimitar and Ince, Hüseyin and Nienaber, Christoph A and Radunski, Henning and Boekstegers, Peter and Horstkotte, Jan and Mueller, Ralf and Müller, Karin and Rasp, Oliver and TROPICAL-ACS Investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10104, pp. 1747 - 1757
Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous... 
ELUTING STENTS | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | THERAPY | TICAGRELOR | TREATMENT PATTERNS | ACADEMIC RESEARCH CONSORTIUM | PRASUGREL | DIPHOSPHATE RECEPTOR INHIBITOR | MYOCARDIAL-INFARCTION PATIENTS | PLATELET REACTIVITY | Myocardial Infarction - epidemiology | Acute Coronary Syndrome - epidemiology | Drug Administration Schedule | Hemorrhage - epidemiology | Humans | Middle Aged | Europe - epidemiology | Male | Prasugrel Hydrochloride - adverse effects | Ticlopidine - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Acute Coronary Syndrome - therapy | Clopidogrel | Female | Stroke - epidemiology | Hemorrhage - chemically induced | Prasugrel Hydrochloride - administration & dosage | Drug Monitoring | Percutaneous Coronary Intervention | Platelet Aggregation Inhibitors - adverse effects | Transluminal angioplasty | Care and treatment | Coronary heart disease | Cardiac patients | Analysis | Anticoagulants | Heart attacks | Blood platelets | Angioplasty | Clinical trials | Acute coronary syndromes | Drug therapy | Patients | Clinical outcomes | Myocardial infarction | Intervention | Medical services | Bleeding | Consortia | Randomization | Motivation | Bioindicators | Inhibition | Cerebral infarction | Stroke | Test procedures | Health risks | Thrombosis | Coronary vessels | Biomarkers | Infarction | Cardiovascular diseases | Platelets | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 09/2016, Volume 134, Issue 11, pp. 780 - 792
Journal Article